glp-1 mash The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis Exploring the Potential of GLP-1

Prescribing trends are being driven by growing evidence that suggest GLP-1s provide benefits well beyond glucose control and weight management, spanning therapy areas from cardiovascular risk reduction to potential applications in neurological conditions such as Parkinsons disease 2

Weight change and risk of venous thromboembolism: the Troms study

Patients taking Wegovy lost an average of 35 lbs compared to 6 lbs in the placebo group

Peripheral tissue ages faster

Plasma concentration of ghrelin peaks under fasting conditions before the meal and then levels off after meal to a nadir to increase again after gastric emptying before next meal (14)

This introduces an additional source of potential dosing error